 Idiopathic pulmonary fibrosis prognosis remains severe, in particular for IPF, the most common entity. Moreover, current treatment options are largely ineffective and do not change the natural course of the disease. Pre-clinical evidence supports somatostatin receptors expression in the lung of patients with IPF. Recently new PET tracers Somatostatin analogues labelled with 68Gallium, specifically binding to somatostatin receptors, have been developed and are used in neuroendocrine tumours clinical trials. 